EMN29 approval in Spain and the USA

The EMN is very happy to announce that the EMN29 study has been approved in Spain and in the USA.

This is the first time that our network activates a trial with the partners in the States, and we are eager to further invest in this collaboration also for future projects!

The EMN29 is certainly a very interesting study, comparing the all-oral combination Selinexor-Pomalidomide-dexamethasone vs Elotuzumab-Pomalidomide-dexamethason in patients with relapsed/refractory multiple myeloma (1 to 4 prior lines).

Approvals also in the other involved countries and the inclusion of the first patients are expected soon.

We are extremely honored to be able to provide patients with more, effective treatment options and to improve their survival and qualitiy of life.